Mountain States Tumor Institute Inc

What it reported doing in 2019

Oncology & Research: St. Luke's Mountain States Tumor Institute (MSTI) is a wholly owned subsidiary of St. Luke's Regional Medical Center and one of the Northwest's most respected cancer care centers. For over 50 years, St. Luke's has been dedicated to the study, prevention, and treatment of cancer. St. Luke's MSTI patients can now receive care in 8 different locations in the communities we serve. A comprehensive offering of pediatric and adult inpatient and outpatient services comprise the St. Luke's MSTI community cancer program. These services include medical and radiation oncology, blood and marrow transplant, genetic counseling, breast care, gynecologic, urologic, and hepatobiliary subspecialties as well as a fully integrated supportive oncology program that encompasses cancer rehabilitation, patient financial advocacy, integrative medicine, nutritional counseling, palliative care, psychiatry, social work, spiritual care and survivorship services. Additionally MSTI has a robust clinical research program with specimen banking and a biorepository. All St. Luke's MSTI sites are accredited as part of St. Luke's Regional Medical Center, Ltd. St. Luke's is accredited by the Joint Commission on the Accreditation of Healthcare Organizations. The laboratories serving St. Luke's MSTI are certified by the College of American Pathologists. St. Luke's MSTI has been accredited by the American College of Surgeons (ACoS) Commission on Cancer since 1977, and is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT). Accreditations are performed on a three-year cycle. Because of its nationally recognized expertise in cancer care, St. Luke's MSTI is invited to participate in numerous clinical research protocols in cooperation with regional and national cancer research groups and pharmaceutical companies. Among these research groups are the National Cancer Institute, Children's Oncology Group, and The Pacific Cancer Research Consortium (PCRC), which brings together community cancer treatment centers in the Western United States to form an NCI Community Oncology Research Program (NCORP) Community Site. Since its founding in 1969, St. Luke's MSTI has been committed to cancer research. Physicians at St. Luke's MSTI strongly endorse clinical trials. The focus of oncology professionals is on improved cure rates, more effective treatments with fewer side effects, longer survival, and improved quality of life. Clinical research advances science and ensures that patient care approaches the highest possible level of quality. Patients who participate in clinical trials have the opportunity to advance evidence-based medicine. More recently, society requests we help them understand the cost of treatment-examining not just financial obstacles, but social and resource-draining obstacles aswell. This clinical research work is known as Cancer Care Delivery Research. As St. Luke's MSTI has grown, the commitment to research has deepened. While the vast majority of research activity has involved participation in cooperative group trials, St. Luke's MSTI also participates in pharmaceutical-sponsored and investigator-initiated clinical research.Clinical research services are available at all five St. Luke's MSTI cancer treatment clinics throughout Southwest and South Central Idaho. These clinics represent the regional direction of the entire St. Luke's MSTI program. Adult medical, gynecologic, urologic, hepatobiliary, and radiation oncology research studies are offered at all St. Luke's MSTI facilities. Pediatric and autologous stem cell transplant research opportunities are offered only at the Boise site. The St. Luke's MSTI research mission is "To improve outcomes and quality of life of patients with cancer and blood disorders through research." Its vision is "To transform cancer care by aligning with MSTI physicians and other providers to deliver advanced, quality, seamless patient care and help patients achieve their best outcome and q

Financial Efficiency

• Mission deployment rate: 86.8%; rating input score 87
• Program expense ratio: 94.9%; rating input score 95
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
• Pay-setting controls: 0 of 6 controls in place; rating input score 0
  • Compensation committee: Missing
  • Independent consultant: Missing
  • Other Form 990s reviewed: Missing
  • Written employment contract: Missing
  • Compensation survey or study: Missing
  • Board or committee approval: Missing
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 62.5%; rating input score 62; 17th percentile among comparable filings
• Governance controls: 7 of 9 controls in place; rating input score 78
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Fail
  • Other executive compensation review process: Fail
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 8.4%; rating input score 72; 72nd percentile among comparable filings
• Total-asset coverage ratio: 0; rating input score 0; 0th percentile among comparable filings
• Liabilities to assets ratio: Limited
• Officer compensation ratio: 0.2%; rating input score 91; 91st percentile among comparable filings

Growth

• Program expense growth: 7.9% per year; rating input score 100; 71st percentile among comparable filings
• Revenue growth: 10.3% per year; rating input score 100; 82nd percentile among comparable filings
• Asset growth: -21.7% per year; rating input score 0; 1st percentile among comparable filings